Martin Peifer

List of Publications by Citations

Source: https://exaly.com/author-pdf/4905996/martin-peifer-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94 citations 45 h-index 94 g-index

94 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
89	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015 , 524, 47-53	50.4	1061
88	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012 , 44, 1104-10	36.3	919
87	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. <i>Science Translational Medicine</i> , 2010 , 2, 62ra93	17.5	646
86	PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. <i>Cancer Research</i> , 2009 , 69, 3256-61	10.1	411
85	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. <i>Cancer Discovery</i> , 2011 , 1, 78-89	24.4	389
84	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015 , 526, 700-	450.4	347
83	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. <i>Cancer Cell</i> , 2017 , 31, 270-285	24.3	231
82	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 18351-6	11.5	226
81	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. <i>Nature Genetics</i> , 2017 , 49, 65-74	36.3	220
80	Testing for directed influences among neural signals using partial directed coherence. <i>Journal of Neuroscience Methods</i> , 2006 , 152, 210-9	3	218
79	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. <i>Genome Biology</i> , 2015 , 16, 133	18.3	212
78	Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1727-40	15.9	205
77	Mutational dynamics between primary and relapse neuroblastomas. <i>Nature Genetics</i> , 2015 , 47, 872-7	36.3	191
76	Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. <i>Clinical Cancer Research</i> , 2012 , 18, 4682-90	12.9	191
75	A crucial requirement for Hedgehog signaling in small cell lung cancer. <i>Nature Medicine</i> , 2011 , 17, 1504	- 8 50.5	188
74	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014 , 5, 3518	17.4	173
73	CD74-NRG1 fusions in lung adenocarcinoma. <i>Cancer Discovery</i> , 2014 , 4, 415-22	24.4	173

(2015-2016)

72	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016 , 22, 4837-4847	12.9	168
71	Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. <i>Cancer Research</i> , 2010 , 70, 868-74	10.1	165
7°	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <i>Nature Communications</i> , 2018 , 9, 1048	17.4	152
69	ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. <i>Clinical Cancer Research</i> , 2011 , 17, 7394-401	12.9	147
68	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013 , 123, 1732-40	15.9	142
67	A framework for identification of actionable cancer genome dependencies in small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 17034-9	11.5	138
66	Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. <i>Science Translational Medicine</i> , 2012 , 4, 141ra91	17.5	119
65	Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2018 , 9, 727	17.4	116
64	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018 , 362, 1165-1170	33.3	115
63	High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). <i>PLoS ONE</i> , 2009 , 4, e7273	3.7	109
62	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 453-74	8.9	106
61	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018 , 8, 600-615	24.4	96
60	Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS ONE, 2011, 6, e19601	3.7	95
59	K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 606-616	8.9	84
58	Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. <i>Cancer Discovery</i> , 2014 , 4, 246-57	24.4	82
57	Parameter estimation in ordinary differential equations for biochemical processes using the method of multiple shooting. <i>IET Systems Biology</i> , 2007 , 1, 78-88	1.4	75
56	Genomic Amplification of (PD-L1) in Small-Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 1220-122	.6 2.9	74
55	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1049-57	8.9	7 ²

54	UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors. <i>Cell</i> , 2019 , 176, 505-519.e22	56.2	68
53	Hybrid optimization method with general switching strategy for parameter estimation. <i>BMC Systems Biology</i> , 2008 , 2, 26	3.5	65
52	Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. <i>Cancer Research</i> , 2017 , 77, 3040-3056	10.1	59
51	Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. <i>Cell</i> , 2021 , 184, 2239-2254.e39	56.2	57
50	Transcription-induced mutational strand bias and its effect on substitution rates in human genes. <i>Molecular Biology and Evolution</i> , 2009 , 26, 131-42	8.3	52
49	Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. <i>Nature Communications</i> , 2018 , 9, 697	17.4	51
48	Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. <i>Gut</i> , 2016 , 65, 1296-305	19.2	49
47	Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group. <i>British Journal of Cancer</i> , 2015 , 113, 1704-11	8.7	48
46	Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. <i>Cell Reports</i> , 2016 , 16, 644-56	10.6	48
45	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. <i>Oncolmmunology</i> , 2017 , 6, e1320626	7.2	47
44	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	41
43	Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. <i>Genome Biology</i> , 2015 , 16, 7	18.3	39
42	Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. <i>Nucleic Acids Research</i> , 2010 , 38, 6985-96	20.1	36
41	Mechanisms of Primary Drug Resistance in -Amplified Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5527-5536	12.9	35
40	Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. <i>Journal of Pathology</i> , 2017 , 243, 242-254	9.4	35
39	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. <i>Cell Reports</i> , 2017 , 20, 2833-2845	10.6	34
38	Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. <i>Nature Cell Biology</i> , 2020 , 22, 896-906	23.4	30
37	Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2017 , 8, 153	17.4	29

(2020-2013)

36	Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer. <i>Journal of Pathology</i> , 2013 , 231, 505-16	9.4	28
35	The evolutionary history of 2,658 cancers		28
34	yylncT Defines a Class of Divergently Transcribed lncRNAs and Safeguards the T-mediated Mesodermal Commitment of Human PSCs. <i>Cell Stem Cell</i> , 2019 , 24, 318-327.e8	18	27
33	Label-Free Protein-RNA Interactome Analysis Identifies Khsrp Signaling Downstream of the p38/Mk2 Kinase Complex as a Critical Modulator of Cell Cycle Progression. <i>PLoS ONE</i> , 2015 , 10, e01257	743 ⁵⁷	26
32	Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes		25
31	Copy-number analysis and inference of subclonal populations in cancer genomes using Sclust. <i>Nature Protocols</i> , 2018 , 13, 1488-1501	18.8	24
30	Exponential decay of GC content detected by strand-symmetric substitution rates influences the evolution of isochore structure. <i>Molecular Biology and Evolution</i> , 2008 , 25, 362-74	8.3	22
29	Testing for phase synchronization. <i>Physics Letters, Section A: General, Atomic and Solid State Physics</i> , 2007 , 366, 382-390	2.3	22
28	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. <i>Blood</i> , 2021 , 137, 646-660	2.2	22
27	Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 54-65	5	21
26	Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. <i>PLoS ONE</i> , 2015 , 10, e0129544	3.7	21
25	Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. <i>PLoS ONE</i> , 2010 , 5, e8919	3.7	19
24	Non-parametric identification of non-linear oscillating systems. <i>Journal of Sound and Vibration</i> , 2003 , 267, 1157-1167	3.9	16
23	Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells. <i>Oncotarget</i> , 2018 , 9, 9838-9851	3.3	13
22	Integrative Analysis of Pleomorphic Dermal Sarcomas Reveals Fibroblastic Differentiation and Susceptibility to Immunotherapy. <i>Clinical Cancer Research</i> , 2020 , 26, 5638-5645	12.9	11
21	Acquisition of the recurrent Gly101Val mutation in confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (). <i>Haematologica</i> , 2019 , 104, e540	6.6	11
20	Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains. <i>Clinical Cancer Research</i> , 2021 , 27, 1131-1138	12.9	11
19	Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies. <i>BMC Gastroenterology</i> , 2020 , 20, 417	3	10

18	Mixing properties of the RBsler system and consequences for coherence and synchronization analysis. <i>Physical Review E</i> , 2005 , 72, 026213	2.4	10
17	On studentising and blocklength selection for the bootstrap on time series. <i>Biometrical Journal</i> , 2005 , 47, 346-57	1.5	8
16	ATM activity in T cells is critical for immune surveillance of lymphoma in vivo. <i>Leukemia</i> , 2020 , 34, 771-7	86 0.7	8
15	An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. <i>Blood Cancer Discovery</i> , 2021 , 2, 70-91	7	7
14	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3183-3183	15.9	7
13	Chromothripsis followed by circular recombination drives oncogene amplification in human cancer. <i>Nature Genetics</i> , 2021 , 53, 1673-1685	36.3	7
12	Variations in substitution rate in human and mouse genomes. <i>Physical Review Letters</i> , 2004 , 93, 208102	7.4	6
11	Is there an acceleration of the CpG transition rate during the mammalian radiation?. <i>Bioinformatics</i> , 2008 , 24, 2157-64	7.2	5
10	CGARS: cancer genome analysis by rank sums. <i>Bioinformatics</i> , 2014 , 30, 1295-6	7.2	4
9	BISTABILITY AND SELF-OSCILLATIONS IN CELL CYCLE CONTROL. <i>International Journal of Bifurcation and Chaos in Applied Sciences and Engineering</i> , 2006 , 16, 1057-1066	2	4
8	CaMuS: simultaneous fitting and de novo imputation of cancer mutational signature. <i>Scientific Reports</i> , 2020 , 10, 19316	4.9	3
7	Loss of TP53 mediates suppression of Macrophage Effector Function via Extracellular Vesicles and PDL1 towards Resistance against Chemoimmunotherapy in B-cell malignancies		2
6	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer <i>Npj Precision Oncology</i> , 2021 , 5, 102	9.8	2
5	iRODS metadata management for a cancer genome analysis workflow. <i>BMC Bioinformatics</i> , 2019 , 20, 29	3.6	1
4	COSINE: A web server for clonal and subclonal structure inference and evolution in cancer genomics. <i>Zoological Research</i> , 2022 , 43, 75-77	3.4	1
3	Variant profiling of colorectal adenomas from three patients of two families with MSH3-related adenomatous polyposis. <i>PLoS ONE</i> , 2021 , 16, e0259185	3.7	1
2	A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021 , 138, 712-712	2.2	
1	Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients. <i>Blood</i> , 2018 , 132, 4119-4119	2.2	